Children, particularly those with developmental or cognitive challenges, often have trouble swallowing pills, while elderly ... in 2025 to USD 28.88 billion by 2033, exhibiting a CAGR of 7.38% ...

Considering Teva’s extended-release version of Austedo won a key approval in 2023, ramped-up competition in 2025 is something the team at Evercore ISI had anticipated. Even so, this year’s fir ...

Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T ...

Axsome grants Teva a license to sell generic Auvelity starting in 2038 or 2039, resolving all ongoing patent litigation. Axsome's Q4 and full-year 2024 Auvelity sales are expected at $92.6M and $ ...

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and ...

The research could further complicate the polarized politics of abortion because the drug in the study is the key ingredient in a pill used for emergency contraception. By Pam Belluck and Emily ...

Some posts related to obtaining abortion pills were recently hidden on Instagram and Facebook and some accounts were suspended, before being later restored. By Claire Cain Miller Kate Conger and ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone.

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...